Strain Data Sheet

RBRC02287

Strain Information

Image
BRC No.RBRC02287
TypeTargeted Mutation and TransgeneCartagena
SpeciesMus musculus
Strain nameC57BL/6-St3gal4<tm1.2Bsi> Tg(CAG-flp)1Bsi
Former Common nameST34(#9 CAGflep)C57BL/6J, #9 CAGflep
H-2 Haplotype
ES Cell lineMS12 [C57BL/6]
Background strainC57BL/6JJcl
Appearance
Strain development
Strain description
Colony maintenance
References
Sialyltransferase ST3Gal IV deletion protects against temporal lobe epilepsy.
Paitoon Srimontri, Shogo Endo, Toshiro Sakamoto, Yoshiaki Nakayama, Akira Kurosaka, Shigeyoshi Itohara, Yoshio Hirabayashi, Keiko Kato
J. Neurochem., 131(5):675-87 (2014). 25066807

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Frtyeast FRT (flippase recombination target) site9Frt
St3gal4ST3 beta-galactoside alpha-2,3-sialyltransferase 49St3gal4targeted mutation 1.2, RIKEN BSI
loxPphage P1 loxP9loxP
loxPphage P1 loxP9loxP
FLPyeast flippase recombinaseUNFLPCAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA)

Phenotype

Annotation by Mammalian phenotyhpe ontology
  • abnormal conditioned emotional response(MP:0002806)

  • abnormal insulin-like growth factor I level(MP:0008831)

  • abnormal sleep pattern(MP:0001501)

  • behavioral despair(MP:0002573)

  • decreased frequency of paradoxical sleep(MP:0012286)
    • more 5 phenotypes
  • decreased growth hormone level(MP:0005136)

  • decreased kindling response(MP:0001500)

  • increased anxiety-related response(MP:0001363)

  • increased coping response(MP:0003063)

  • increased fear-related response(MP:0003459)
    • Detailed phenotype data

    Ordering Information

    Donor DNAマウス ST3Gal IV(欠損), CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA), 酵母 FLP組換え酵素遺伝子, 酵母 FRT, P1 ファージ loxP
    Research applicationCre/loxP system
    FLP/frt system
    Metabolism Research
    Mouse Models for Human Disease
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. 1. The RECIPIENT agrees to use BIOLOGICAL RESOURCE only for academic research which is expected to be publicized in scientific papers.
    2. The RECIPIENT will obtain a prior written consent on the use of BIOLOGICAL RESOURCE from the DEPOSIOR/DEVELOPER. At the same time, the RECIPENT will give the DEPOSITOR/DEVELOPER the details of the research project using BIOLOGICAL RESOURCE for the DEPOSITOR/DEVELOPER to determine whether research collaboration is appropriate.
    3. If the DEPOSITOR/DEVELOPER determines that the informed research project requires collaboration, a separate agreement will be formulated by both parties to establish rules such as handling of the research results.
    4. If the DEPOSITOR/DEVELOPER determines that the informed research project does not requie collaboration, the RECIPIENT agrees to cite the literatire(s) designated by the DEPOSITOR/DEVEVLOPER when publicizing the research results obtained from use of BIOLOGICAL RESOURCE, and to discuss with the DEPOSITOR/DEVELOPER when application for any patents is considered.
    5. If the RECIPIENT wants to crossbreed BIOLOGICAL RESOURCE with other genetically engineered mice, the RECIPIENT will obtain a prior written consent from the DEPOSITOR/DEVELOPER.
    6. The RECIPIENT will not distribute the BIOLOGICAL RESOURCE to any other individual or entity.
    DepositorYoshio Hirabayashi (RIKEN)
    Strain Statusan icon for Frozen embryosFrozen embryos
    Strain AvailabilityRecovery and QC required prior to distribution
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. CAGGS MTA (English)
    5. Acceptance of responsibility for living modified organism (Japanese / English)

    BRC mice in Publications

    No Data